Current status and use of short/medium-term models for assessment of carcinogenicity of human pharmaceuticals: Regulatory perspectives

Toxicology Letters

Volumn 112-113, Issue , 2000, Pages 567-572

  Van Der Laan, Jan Willem ^a  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

Carcinogenicity; Regulatory acceptance; Transgenic animals

Indexed keywords

PROTEIN P53; RAS PROTEIN;

ANIMAL MODEL; BIOASSAY; BIOTECHNOLOGY; CARCINOGENICITY; CONFERENCE PAPER; DRUG DEVELOPMENT; DRUG SAFETY; DRUG SCREENING; LIVER CARCINOGENESIS; MOUSE; NONHUMAN; ONCOGENE H RAS; ORGANIZATION AND MANAGEMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; RAT; REGULATORY MECHANISM; STANDARDIZATION; TECHNIQUE; TRANSGENIC ANIMAL; XERODERMA PIGMENTOSUM;

ANIMALS; ANIMALS, NEWBORN; BIOTECHNOLOGY; CARCINOGENICITY TESTS; DISEASE MODELS, ANIMAL; DRUG APPROVAL; HUMANS; INTERNATIONAL COOPERATION; MICE; MICE, TRANSGENIC; RATS;

ANIMALIA; MUS MUSCULUS; RODENTIA;

EID: 0034654291     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-4274(99)00228-3     Document Type: Conference Paper

References (11)

1. Contrera J.F., Jacobs A.C., DeGeorge J.J. Carcinogenicity testing and evaluation of regulatory requirements for pharmaceuticals. Regul. Pharmacol. Toxicol. 25:1997;130-145.
2. De Vries A., Van Oostrum C.T.h.M., Hofhuis F.M.A., Dortant P.M., Berg R.J.W., De Gruijl F.R., Wester P.W., Van Kreijl C.F., Capel P.J.A., Van Steeg H., Verbeek S.J. Increased susceptibility to ultraviolet-B and carcinogens of mice lacking the DNA excision repair gene XPA. Nature. 377:1995;169-173.
3. Flammang T.J., Von Tungeln L.S., Kadlubar F.F., Fu P.P. Neonatal mouse assay for tumorigenicity: alternative to the chronic rodent bioassay. Regul. Pharmacol. Toxicol. 25:1997;230-240.
4. Fujii K. Evaluation of the newborn mouse model for chemical tumorigenesis. Carcinogenesis. 12:1991;1409-1415.
5. ICH, 1997. International Conference on Harmonisation of Technical Requirements for the Registration of Pharmaceuticals for Human Use. Harmonised guideline. Testing for Carcinogenicity of Pharmaceuticals, CPMP/ICH/299/95.
6. Ito N., Hasegawa R., Imaida K., Kurata Y., Hagiwara A., Shirai T. Effect of ingestion of 20 pesticides in combination at acceptable daily intake levels on rat liver carcinogenesis. Fd. Chem. Toxicol. 33:1995;159-163.
7. Tennant R.W. Stratification of rodent carcinogenicity bioassay results to reflect relative human hazard. Mutat. Res. 286:1993;111-118.
8. Tennant R.W., French J.E., Spalding J.W. Identifying chemical carcinogens and assessing potential risk in short-term bioassays using transgenic mouse models. Environ. Health Perspect. 103:1995;942-950.
9. Van der Laan J.W. Testing for Carcinogenic Potential. Regulatory Viewpoint. D'Arcy P.F., Harron D.W.G. Proceedings of the Third International Conference on Harmonisation Yokohama 1995. 1996;269-273 Greystone Books Ltd, Antrim, Northern Ireland.
10. Van Oosterhout J.P.J., Van Der Laan J.W., De Waal E.J., Olejniczak K., Hilgenfeld M., Schmidt V., Bass R. The utility of two rodent species in carcinogenic risk assessment of pharmaceuticals in Europe. Regul. Pharmacol. Toxicol. 25:1997;6-17.
11. Venkatalacham S., Shi Y.-P., Jones S.N., Vogel H., Bradley A., Pinkel D., Donehower L.A. Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation. EMBO J. 17:1998;4657-4667.